Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 2, 2020, Pages

  Romero, Sally AD ^a   Young, Katie ^b   Hickey, Martha ^c   Su, H Irene ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CONTRACEPTIVE AGENT;

ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; HYSTEROSCOPY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PROTECTION; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; UTERUS DISEASE; UTERUS MYOMA; VAGINA BLEEDING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; CONFIDENCE INTERVAL; DRUG EFFECT; ENDOMETRIUM TUMOR; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; META ANALYSIS; MORTALITY; POLYP; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR RECURRENCE; UTERUS; UTERUS BLEEDING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; NEOPLASM RECURRENCE, LOCAL; POLYPS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN; UTERINE HEMORRHAGE; UTERUS;

EID: 85098927008     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007245.pub4     Document Type: Review

References (30)

1. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen treated women. BJOG 2007;114(12):1510–5. x-wiley/crsRef/15908129
2. Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstetrics and Gynecology 2013;121(5):943-50. x-wiley/crsRef/15908130
3. Gardner FJ, Konje JC, Abrams KR, Brown LJ, Khanna S, Al-Azzawi F, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000;356(9243):1711-7. x-wiley/crsRef/15908132
4. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using levonorgestrel releasing intrauterine system: long-term follow-up of a randomised control trial. Gynecologic Oncology 2009;114(3):452-6. x-wiley/crsRef/15908133
5. Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 2008;11(3):252-7. x-wiley/crsRef/15908135
6. Omar H, Elkhayat W, Aboulkasem M. The use of levonorgestrel-releasing intrauterine system in prevention of endometrial pathology in women with breast cancer treated with tamoxifen. International Journal of Medicine 2010;3(1):327-330. x-wiley/crsRef/15908137
7. ACOG Committee Opinion No 601. Tamoxifen and uterine cancer. Obstetrics and Gynecology 2014;123(6):1394-7.
8. ACOG Committee Opinion No 631. Endometrial intraepithelial neoplasia. Obstetrics and Gynecology 2015;125(5):1272-8.
9. American Cancer Society. How common is breast cancer? www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html accessed 16 October 2020.
10. Davies C, Pan H, Godwin J, Gray R, Arriagada R, et al for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381(9869):805-16.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378(9793):771-84.
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386(10001):1341-52.
13. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 1998;90(18):1371-88.
14. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using levonorgestrel releasing intrauterine system: long-term follow-up of a randomised control trial. Gynecologic Oncology 2009;114(3):452-6.
15. Gizzo S, Di Gangi S, Bertocco A, Noventa M, Fagherazzi S, Ancona E, et al. Levonorgestrel intrauterine system in adjuvant tamoxifen treatment: balance of breast risks and endometrial benefits — systematic review of literature. Reproductive Science 2014;21(4):423-31.
16. McMaster University (developed by Evidence Prime) GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 9 May 2020. Available at gradepro.org.
17. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A cases control study on hormone therapy as a risk factor for breast cancer in Finland. International Journal of Cancer July 2009;126(2):483-9.
19. Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database of Systematic Reviews 2020, Issue 9. Art. No: CD012658. [DOI: 10.1002/14651858.CD012658.pub2]
20. National Comprehensive Cancer Network. Breast Cancer (Version 6.2020). Available at www.nccn.org/professionals/physician_gls/pdf/breast.pdf Accessed 16 October 2020.
21. Philip S, Taylor AH, Konje JC, Habiba M. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen. Journal of Obstetrics and Gynaecology 2019;39(8):1117-22.
22. Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging 2008;8(1):135-45.
23. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
24. Scommegna A, Pandya GN, Christ M, Lee AW, Cohen MR. Intrauterine administration of progesterone by a slow releasing device. Fertility and Sterility 1970;21(3):201-10.
25. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam Pa. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertility and Sterility 2008;90(1):17-22.
26. Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstetrics and Gynecology 2013;121(5):943-50.
27. Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41(4):353-62.
28. Chin J, Hickey M, Konje J. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD007245. [DOI: 10.1002/14651858.CD007245]
29. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No: CD007245. [DOI: 10.1002/14651858.CD007245.pub2]
30. Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No: CD007245. [DOI: 10.1002/14651858.CD007245.pub3]